Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Testosterone administration to men is known to decrease high-density lipoprotein cholesterol (HDL-C) and the subclasses HDL 2 and HDL 3. It also might increase the number of small, dense, low-density lipoprotein cholesterol (LDL-C) particles in hypogonadal men. The decrease in HDL-C and in LDL-C size is potentially mediated by hepatic lipase activity, which hydrolyzes lipoprotein phospholipids and triacylglycerol. To determine how HDL-C and LDL-C particles are affected by testosterone administration to eugonadal men, testosterone was administered as a supraphysiological dose (600 mg/wk) for 3 wk to elderly, obese, eugonadal men before elective hip or knee surgery, and lipids were measured by routine methods and by density gradient ultracentrifugation. Hepatic lipase activity increased >60% above baseline levels, and HDL-C, HDL 2, and HDL 3 significantly declined in 3 wk. In addition, the LDL-C peak particle density and the amount of LDL-C significantly increased. Testosterone is therefore a potent stimulator of hepatic lipase activity, decreasing HDL-C, HDL 2, and HDL 3 as well as increasing LDL particle density changes, all associated with increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 1×
“That HDL-C decreases with T administration might be important for long-term use of T in men, because low HDL-C, including low HDL2 and low HDL3, is associated with an increased risk for cardiovascular disease (3, 14, 26).”
BackgroundLamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 1×
“Recently, intramuscular T in supraphysiological dosages has been administered to men to evaluate T effects on body composition and metabolism (10, 29) and to determine whether T could decrease length of hospital stay after knee or hip replacement (1).”
BackgroundIntramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis
Whitsel, E. A., Boyko, E. J., Matsumoto, A. M., Anawalt, B. D., & Siscovick, D. S. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00833-6 · Cited by 240 · cited 1×
“Most studies in hypogonadal men do not find a change in HDL3 after T administration (6, 33, 39), but some do (9); the difference is likely explained by the amount and length of time T was administered.”
BackgroundImpact on Lipoprotein Profile after Long-Term Testosterone Replacement in Hypogonadal Men
Berg, G., Schreier, L., Geloso, G., Otero, P., Nagelberg, A., & Levalle, O. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-20521 · Cited by 27
Cited by
Pathophysiology and types of dyslipidemia in PCOS
Diamanti-Kandarakis, E., Papavassiliou, A. G., Kandarakis, S. A., & Chrousos, G. P. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.07.004 · Cited by 299
Aging and dyslipidemia: A review of potential mechanisms
Liu, H.-H., & Li, J.-J. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.12.001 · Cited by 274
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
McCullough, D., Webb, R., Enright, K. J., Lane, K. E., McVeigh, J., Stewart, C. E., & Davies, I. G. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09616-y · Cited by 62
“Furthermore, 3 weeks of 600 mg/wk Test E administration in inactive ageing males resulted in significant decreases in HDL-C, particularly HDL2 [95].”
BackgroundInfluential
Metadata
- Authors
- Herbst, K. L., Amory, J. K., Brunzell, J. D., Chansky, H. A., & Bremner, W. J.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2003-06-01
- Volume
- 284
- Issue
- 6
- Pages
- E1112-E1118
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2160827677
- Cited by
- 83
- References
- 5
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. https://app.cochat.ai/papers/10.1152/ajpendo.00524.2002
- The paper
- Herbst, K. L., Amory, J. K., Brunzell, J. D., Chansky, H. A., & Bremner, W. J. (2003). Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00524.2002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.